Using the Bruker Fourier RxnLab for real‑time ¹⁹F NMR monitoring helps accelerate pharmaceutical synthesis, enhance process knowledge, and promote more sustainable drug‑development practices.
Image Credit: JLStock/Shutterstock.com
Key advantages and significance of the solution
Integrating ¹⁹F NMR into pharmaceutical operations offers a distinct balance between sensitivity, selectivity, and cost effectiveness. The process enables the accurate tracking of substrates, intermediates, and products, even in complex matrices, without the need for external standards.
Automated data analysis with InsightMR software produces clear kinetic profiles and mechanistic insights, allowing for process intensification, scalability, and compliance with Process Analytical Technology (PAT) and Quality by Design (QbD) standards.
Three key points
- Real-Time Monitoring with 19F NMR: High sensitivity allows for accurate tracking of fluorinated species, offering insights into reaction progress and kinetics to optimize synthesis.
- Automated, User-Friendly Workflows: Integrated hardware and software simplify reaction monitoring for batch and flow chemistry, providing automated and user-friendly workflows.
- Scalable Integration for PAT and QbD: Adaptable Benchtop NMR technologies enable scalable integration for PAT and QbD, supporting growing research and manufacturing needs and ensuring regulatory compliance.
Download the full article to see how ¹⁹F NMR may improve pharmaceutical development processes by providing real-time insights, strong process control, and scalable solutions for the future of drug synthesis.
Download the article here
Acknowledgments
This article has been produced using materials originally authored by Justinas Sakas, Matteo Pennestri, and Alejandro Bara-Estaún at Bruker BioSpin.
About Bruker BioSpin Group
The Bruker BioSpin Group designs, manufactures, and distributes advanced scientific instruments based on magnetic resonance and preclinical imaging technologies. These include our industry-leading NMR and EPR spectrometers, as well as imaging systems utilizing MRI, PET, SPECT, CT, Optical and MPI modalities. The Group also offers integrated software solutions and automation tools to support digital transformation across research and quality control environments.
Bruker BioSpin’s customers in academic, government, industrial, and pharmaceutical sectors rely on these technologies to gain detailed insights into molecular structure, dynamics, and interactions. Our solutions play a key role in structural biology, drug discovery, disease research, metabolomics, and advanced materials analysis. Recent investments in lab automation, optical imaging, and contract research services further strengthen our ability to support evolving customer needs and enable scientific innovation.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.